ONC · BeOne Medicines Ltd. American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ONC by emailGet an email when ONC pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ONC, unsubscribe in one click. Privacy
📣 What ONC Says Is Next
fourth quarter · “Full year 2026 total revenue guidance of $6.2 billion to $6.4 billion SAN CARLOS, Calif. – February 26, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025.”
Company press release, Feb 26, 2026 · SEC filing
2H 2026 · “Anticipate Japan approval for the treatment of first-line gastric cancer. 2H 2026 Hematology”
Company press release, Nov 6, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ONC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ONC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.